Compare DCOY & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCOY | UGRO |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.8M |
| IPO Year | N/A | 2018 |
| Metric | DCOY | UGRO |
|---|---|---|
| Price | $6.07 | $3.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 13.9K | ★ 64.4K |
| Earning Date | 05-16-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,399,438.00 |
| Revenue This Year | N/A | $462.72 |
| Revenue Next Year | N/A | $86.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.11 |
| 52 Week High | $9.57 | $39.68 |
| Indicator | DCOY | UGRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 36.47 |
| Support Level | $4.98 | $2.13 |
| Resistance Level | $6.47 | $3.41 |
| Average True Range (ATR) | 0.88 | 0.38 |
| MACD | -0.16 | 0.17 |
| Stochastic Oscillator | 22.39 | 25.81 |
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees' time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).